| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/08/2004 | WO2003030899A3 Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders |
| 01/08/2004 | WO2003020257A3 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| 01/08/2004 | WO2003003018A3 Method for identifying compounds for the therapy of aging of the cardiovascular system |
| 01/08/2004 | WO2003000859A3 G-protein coupled receptors |
| 01/08/2004 | WO2002095067A3 INTERFERON α-14 POLYMORPHISM |
| 01/08/2004 | WO2002092075A3 Therapeutic delivery of carbon monoxide |
| 01/08/2004 | WO2002083065A3 Peptide antiangiogenic drugs |
| 01/08/2004 | WO2002080952A3 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 01/08/2004 | WO2002072780A3 Igf antagonist peptides |
| 01/08/2004 | WO2002056745A3 Method of treating parkinson's disease |
| 01/08/2004 | WO2002053594A3 Inhibitors of memapsin 2 and use thereof |
| 01/08/2004 | WO2002053522A3 Novel estrogen receptor ligands and methods i |
| 01/08/2004 | WO2002053130A3 Sustained release drug delivery devices with coated drug cores |
| 01/08/2004 | WO2002046458A3 Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof |
| 01/08/2004 | WO2002046225A3 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 01/08/2004 | WO2002045737A3 Methods of treatment involving human mda-7 |
| 01/08/2004 | WO2002036751A3 Human cord blood derived unrestricted somatic stem cells (ussc) |
| 01/08/2004 | WO2001066123A3 Composition consisting of phy906 and chemotherapeutic agents |
| 01/08/2004 | US20040006780 VEGF-modulated genes and methods employing them |
| 01/08/2004 | US20040006245 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain |
| 01/08/2004 | US20040006227 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 01/08/2004 | US20040006208 Comprises three-dimensional structure of bound immunoglobulin complex; antiinflammatory/anticarcinogenic; viricides |
| 01/08/2004 | US20040006143 Aminoalcohol derivatives |
| 01/08/2004 | US20040006135 Combination treatment for depression and anxiety |
| 01/08/2004 | US20040006134 Antiandrogenic biphenyls |
| 01/08/2004 | US20040006133 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | US20040006123 Interleukin-4 gene expression inhibitors |
| 01/08/2004 | US20040006120 Administering to a patient in need of such weight loss or treatment an effective amount of an inverse agonist of histamine H3 receptors, with the proviso that inverse agonist is not thioperamide |
| 01/08/2004 | US20040006116 For therapy of non-insulin dependent diabetes mellitus |
| 01/08/2004 | US20040006115 2-Oxothiazolidine 4-carboxylic acid compounds for promoting desquamation of the skin |
| 01/08/2004 | US20040006111 Transmucosal delivery of proton pump inhibitors |
| 01/08/2004 | US20040006105 Thrombin receptor antagonists |
| 01/08/2004 | US20040006103 Use of chloroquine, hydroxychloroquine and 4 amino-quinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards HIV sensitive strains and towards HIV strains which are resistant to both nucleosidic and non-nucleosidic reverse transcriptase inhibitors and to proteases inhibitors |
| 01/08/2004 | US20040006102 Alkoxy aryl beta2 adrenergic receptor agonists |
| 01/08/2004 | US20040006101 Quinolinone derivatives |
| 01/08/2004 | US20040006100 Administering phenylacetic acid derivative for therapy of Parkinson's disease |
| 01/08/2004 | US20040006098 Induce cytokine biosynthesis in animals |
| 01/08/2004 | US20040006097 For therapy of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis |
| 01/08/2004 | US20040006096 Substituted alkanohydroxamic acids and method of reducing TNFalpha levels |
| 01/08/2004 | US20040006095 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 01/08/2004 | US20040006094 For prophylaxis of ischemic cell death, particularly neuronal cell death, and reduce the likelihood of neuronal cell death in a subject due to a traumatic event |
| 01/08/2004 | US20040006092 Amidine derivatives for treating amyloidosis |
| 01/08/2004 | US20040006091 Therapeutic agents useful for treating or preventing pain |
| 01/08/2004 | US20040006087 Method of treating cancer using FPT inhibitors and antineoplastic agents |
| 01/08/2004 | US20040006083 Pyrazolopyrimidines as therapeutic agents |
| 01/08/2004 | US20040006082 For therapy and prophylaxis of diabetes, diabetic complications, diabetic retinopathy, obesity or asthma, hypoglycemic agent, an improving agent for impaired glucose tolerance, a potentiating agent for insulin sensitivity |
| 01/08/2004 | US20040006081 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity |
| 01/08/2004 | US20040006080 Chemical compounds |
| 01/08/2004 | US20040006079 Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors |
| 01/08/2004 | US20040006073 Method of treating attention deficit hyperactivity disorder |
| 01/08/2004 | US20040006071 Non-nucleoside reverse transcriptase inhibitors |
| 01/08/2004 | US20040006067 Substituted piperidines and methods of use |
| 01/08/2004 | US20040006066 Ring fused pyrazole derivatives as CRF antagonists |
| 01/08/2004 | US20040006063 Dipeptide derivatives |
| 01/08/2004 | US20040006060 Inducing contraception by delivering to a female of child-bearing age a selective estrogen receptor modulator comprising cyclothiocarbamate derivative |
| 01/08/2004 | US20040006057 For therapy of connective tissue disorders, inflammatory disorders, immunology/allergy disorders, infectious diseases, respiratory diseases, cardiovascular diseases, eye diseases, metabolic diseases, central nervous system (CNS) disorders |
| 01/08/2004 | US20040006056 Substituted alkanoic acids |
| 01/08/2004 | US20040006050 Administering substituted phenylsulfonamide for therapy and prophylaxis of Alzheimer's Disease and Down's syndrome |
| 01/08/2004 | US20040006049 For therapy of prostatitis, benign prostate hyperplasia or prostate cancer |
| 01/08/2004 | US20040006046 For therapy and prophylaxis of hyperglycemia |
| 01/08/2004 | US20040006032 Vaccination |
| 01/08/2004 | US20040006021 Pharmaceutical composition comprising factor Vll polypeptides and tranexamic acid |
| 01/08/2004 | US20040006004 This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 |
| 01/08/2004 | US20040006003 Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| 01/08/2004 | US20040005710 Method for producing recombinant viruses using site-specific recombination |
| 01/08/2004 | US20040005598 Comprises nucleotide sequences coding protein upregulated in metastatic prostate cancer (PUMPCn) for diagnosis and treatment of tumors; antiproliferative agents; anticarcinogenic agents |
| 01/08/2004 | US20040005581 Comprises nucleotide sequences coding vanilloid receptor-like receptor (VR4) for diagnosing and treating pain, inflammation, neurodegeneration, cardiovascular, cancer and urogenital diseases; drug screening |
| 01/08/2004 | US20040005576 Comprises polypeptides for diagnosing, prognosing and preventing cancer, nervous system, developmental and metabolic disorders |
| 01/08/2004 | US20040005362 Liquid dosage forms of acid labile drugs |
| 01/08/2004 | US20040005322 Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| 01/08/2004 | US20040005318 Method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided. |
| 01/08/2004 | US20040005316 Use of HMG fragments as anti-inflammatory agents |
| 01/08/2004 | US20040005305 Nutritional composition for treating an immune condition |
| 01/08/2004 | US20040005303 In vivo induction for enhanced function of isolated hepatocytes |
| 01/08/2004 | DE10227269A1 Thiazolderivate Thiazole derivatives |
| 01/08/2004 | DE10226814A1 Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände New drug combinations for the treatment of ischemic conditions |
| 01/08/2004 | CA2744893A1 Aryl carbonyl derivatives as glucokinase activators |
| 01/08/2004 | CA2513143A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | CA2500165A1 Drug composition containing nf-.kappa.b inhibitor |
| 01/08/2004 | CA2494249A1 Novel azasugar derivative and drug containing the same as the active ingredient |
| 01/08/2004 | CA2493854A1 Phosphodiesterase inhibitor |
| 01/08/2004 | CA2493646A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | CA2492080A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 01/08/2004 | CA2492066A1 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | CA2492065A1 Aminoalcohol derivatives_as b3 adrenergic receptor agonist |
| 01/08/2004 | CA2492057A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 01/08/2004 | CA2491427A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | CA2491363A1 Antibodies and uses thereof |
| 01/08/2004 | CA2491271A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 01/08/2004 | CA2491156A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | CA2491053A1 Use of antibodies against flt-1 for the treatment of osteoporosis |
| 01/08/2004 | CA2491002A1 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 01/08/2004 | CA2490950A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | CA2490811A1 Use of organic compounds |
| 01/08/2004 | CA2490411A1 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2490282A1 Use of casein peptides for treating hypertension |
| 01/08/2004 | CA2490261A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | CA2490250A1 Drug composition for blood sugar control |
| 01/08/2004 | CA2490130A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor |
| 01/08/2004 | CA2490129A1 Compositions and methods comprising protein activated receptor antagonists |